ArticleHaematologica2013
Large inter-individual variation of the pharmacodynamic effect of anticoagulant drugs on thrombin generation.
Article in Haematologica, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Ex Vivo Effect of Apixaban on Hemostatic Biomarkers in Children With Heart Disease: A SAXOPHONE Trial Substudy.Journal of the American Heart Association · 2026Trial
- An Insight Into a Potential Antithrombin-Independent Mechanism of Inadequate Heparin Response in Neonates and Infants Undergoing Pediatric Cardiac Surgery: An Exploratory Study.Journal of cardiothoracic and vascular anesthesia · 2026Article
- Heparin and Direct Oral Anticoagulants have Different Effects on the Phases of Activation and Spatial Spread of Blood Coagulation.Thrombosis and haemostasis · 2026Article
- Personalized anticoagulant therapy in venous thromboembolism: current role of direct oral anticoagulants, unmet clinical needs, and future perspectives on Factor XI inhibition.Frontiers in pharmacology · 2026Review
- A comparison of anti-coagulation monitoring tests in ICU patients receiving a continuous infusion of unfractionated heparin.Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine · 2024Article
- Manufacture and Initial Characterisation of RAPIDGels (Basel, Switzerland) · 2024Article
- Bioimpedance Analysis as Early Predictor for Clot Formation Inside a Blood-Perfused Test Chamber: Proof of Concept Using an In Vitro Test-Circuit.Biosensors · 2023Article
- A pilot study of procoagulant platelet extracellular vesicles and P-selectin increase during induction treatment in acute lymphoblastic leukaemia paediatric patients: two new biomarkers of thrombogenic risk?Journal of thrombosis and thrombolysis · 2021Article
- Anticoagulated patients exhibit intact endogenous thrombin potential using ST Genesia unlike the Calibrated Automated Thrombogram.Research and practice in thrombosis and haemostasis · 2021Article
- Inhibition of thrombin generation 12 hours after intake of direct oral anticoagulants.Research and practice in thrombosis and haemostasis · 2020Article
- Assessment of the analytical performances and sample stability on ST Genesia system using the STG-DrugScreen application.Journal of thrombosis and haemostasis : JTH · 2019Article
- Heparins: A Shift of Paradigm.Frontiers in medicine · 2019Article
- Periprocedural management of anticoagulation for atrial fibrillation catheter ablation in direct oral anticoagulant-treated patients.Clinical cardiology · 2018Article
- Prediction of bleeding risk in patients taking vitamin K antagonists using thrombin generation testing.PloS one · 2017Article
- The modification of the thrombin generation test for the clinical assessment of dabigatran etexilate efficiency.Scientific reports · 2016Article
- Unfractionated and Low-Molecular-Weight Heparin and the Phosphodiesterase Inhibitors, IBMX and Cilostazol, BlockFrontiers in veterinary science · 2016Article
- New oral anticoagulants: are coagulation units still required?Thrombosis journal · 2014Article
- Differential in vitro inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosis.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anticoagulation by a standard dosage of an inhibitor of thrombin generation presupposes predictable pharmacokinetics and pharmacodynamics of the anticoagulant. We determined the inter-individual variation of the effect on thrombin generation of a fixed concentration of direct and antithrombin-mediated inhibitors of thrombin and factor Xa. Thrombin generation was determined by calibrated automated thrombinography in platelet-poor plasma from 44 apparently healthy subjects which was spiked with fixed concentrations of otamixaban, melagatran, unfractionated heparin, dermatan sulfate and pentasaccharide. The variability of the inhibitory effect of the different anticoagulants within the population was determined using the coefficient of variation, i.e. the standard deviation expressed as a percentage of the mean. The inter-individual coefficients of variation of the endogenous thrombin potential and peak height before inhibition were 18% and 16%, respectively and became 20%-24% and 24%-43% after inhibition. The average inhibition of endogenous thrombin potential and peak height (ETP, peak) brought about by the anticoagulants was respectively: otamixaban (27%, 83%), melagatran (56%, 63%), unfractionated heparin (43%, 58%), dermatan sulfate (68%, 57%) and pentasaccharide (25%, 67%). This study demonstrates that the addition of a fixed concentration of any type of anticoagulant tested causes an inhibition that is highly variable from one individual to another. In this respect there is no difference between direct inhibitors of thrombin and factor Xa and heparin(-like) inhibitors acting on the same factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.